Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Bionano Genomics

Bionano Genomics (BNGO) Challengers: 3 Biotech Innovators to Buy Instead

With the rising aging population and the emergence of new diseases, the biotech industry appears poised for steady growth. Therefore, three quality biotech stocks, Vanda Pharmaceuticals (VNDA), Organogenesis Holdings (ORGO), and Exelixis (EXEL), could be better catches than Bionano Genomics (BNGO). Read on….

Bionano Genomics (BNGO) vs. Gilead Sciences (GILD): Buy, Hold or Sell these Biotech Stocks?

Bionano Genomics (BNGO) vs. Gilead Sciences (GILD): Buy, Hold or Sell these Biotech Stocks?

As the biotech industry reaches new heights with innovation and the accessibility of big data, let us analyze whether biotech stocks Bionano Genomics and Gilead Sciences are a Buy, Hold, or Sell.

Which Stock Do Investors Consider a Heathier Investment: Bionano Genomics (BNGO) vs. Corcept Therapeutics (CORT)

Which Stock Do Investors Consider a Heathier Investment: Bionano Genomics (BNGO) vs. Corcept Therapeutics (CORT)

The biotech industry is poised for long-term growth supported by government initiatives and the rising prevalence of chronic illnesses. While biotech stocks Bionano Genomics (BNGO) and Corcept Therapeutics (CORT) should benefit from the industry tailwinds, let us determine which stock could be considered a healthier investment.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Are These Biotech Stocks a Buy or Sell for August: Bionano Genomics (BNGO) vs. Cidara Therapeutics (CDTX)?

Underpinned by undeniable growth trends of an aging population, breakthrough therapies, and the inelastic demand for healthcare products and medicines, the biotech industry is expected to perform well in the near term. Given this backdrop, let’s compare two biotech stocks, Bionano Genomics (BNGO) and Cidara Therapeutics (CDTX), to determine if…

Is Bionano Genomics (BNGO) a Buy or Sell this Week?

Genomic testing devices manufacturer Bionano Genomics (BNGO) is witnessing steady revenue growth. However, unfortunately, it did not translate into a bottom-line improvement. Moreover, as BNGO faces the possibility of delisting, is it worth buying now? Keep reading.

Is Now the Time to Buy Bionano Genomics (BNGO)?

Biotech company Bionano Genomics (BNGO) has significant topline growth under its belt. However, its bottom line outlook is concerning. Would it be wise to invest in the stock now? Let’s look at some of its financial metrics to find out….

Bionano Genomics Lags On This Crucial Metric

There's only one way to succeed in lab hardware. Despite a promising platform, Bionano Genomics remains a long way from sustainable success.

inkl

Read news from The Economist, FT, and more,
with one subscription

Meme-Stock Mania Is Leaving These Genomics Stocks

Meme-Stock Mania Is Leaving These Genomics Stocks

A handful of biotech stocks were catapulted higher by short squeezes. Whether they will recover their losses is an open question.

Looking Into Bionano Genomics's Return On Capital Employed

Looking Into Bionano Genomics's Return On Capital Employed

Bionano Genomics (NASDAQ:BNGO) brought in sales totaling $5.70 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 30.52%, resulting in a loss of $29.95 million.

Bionano Genomics's Earnings Outlook

Bionano Genomics's Earnings Outlook

Bionano Genomics (NASDAQ:BNGO) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Bionano Genomics will report an earnings per share (EPS) of $-0.07.

Bionano Genomics's Return On Capital Employed Insights

Bionano Genomics's Return On Capital Employed Insights

Benzinga Pro data, Bionano Genomics (NASDAQ:BNGO) reported Q4 sales of $6.30 million. Earnings fell to a loss of $22.95 million, resulting in a 10.58% decrease from last quarter.

Bionano Genomics's Earnings Outlook

Bionano Genomics's Earnings Outlook

Bionano Genomics (NASDAQ:BNGO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate that Bionano Genomics will report an earnings per share (EPS) of $-0.06.

People

Kritika SarmahHer

Steve Reitmeister

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Gilead Sciences

Organogenesis Holdings Inc

Bionano Genomics

Bionano Genomics Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

249,186 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play